Evidence map›Paper›PMID 41878264›Full record

ArticleFrontiers in cellular and infection microbiology2026

Low levels of the second messenger c-di-GMP enhance tolerance and resistance to meropenem in

Tarcisio Brignoli, Silvia Ferrara, Edoardo Labrini, Giovanni Bertoni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tarcisio BrignoliDepartment of Biosciences, Università Degli Studi di Milano, Milan, Italy.
Silvia FerraraDepartment of Biosciences, Università Degli Studi di Milano, Milan, Italy.
Edoardo LabriniDepartment of Biosciences, Università Degli Studi di Milano, Milan, Italy.
Giovanni BertoniDepartment of Biosciences, Università Degli Studi di Milano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The carbapenem antibiotic meropenem is often used to treat life-threatening infections caused by Methods: We used Results: We show that low intracellular c-di-GMP levels increase meropenem resistance and tolerance at sub-inhibitory concentrations, whereas high c-di-GMP diminishes both traits. Importantly, c-di-GMP status shapes the entire response trajectory, from exponential growth to the stationary phase. Furthermore, we show that c-di-GMP modulates meropenem response through mechanism(s) independent of Hfq-mediated porin repression and exerts a dominant effect over CCR-driven regulation. Conclusion: This study supports the notion that

Indexed as

Anti-Bacterial AgentsCyclic GMPDrug Resistance, BacterialMeropenemPseudomonas aeruginosaCatabolite RepressionGene Expression Regulation, BacterialHost Factor 1 ProteinMicrobial Sensitivity TestsPorinsSecond Messenger SystemsThienamycinsAnti-Bacterial Agentsbis(3',5')-cyclic diguanylic acidCyclic GMPHost Factor 1 ProteinMeropenemPorinsThienamycinsantibiotic resistanceantibiotic tolerancecarbapenemscarbon catabolite repressionc-di-GMPHfqmeropenemPseudomonas aeruginosa

Identifiers

PMID41878264
PMCPMC13006659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.